Two abstracts presented at the American Thoracic Society 2024 International Conference analyzed the phase 3 LIBERTY COPD BOREAS trial, finding that dupilumab improves pre- and post-bronchodilator lung ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback